BiotechTube

JSP191

Phase 1Terminated
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lower-risk Myelodysplastic Syndrome

Conditions

Lower-risk Myelodysplastic Syndrome

Trial Timeline

Jun 19, 2023 → Oct 21, 2024

NCT ID
NCT05903274

About JSP191

JSP191 is a phase 1 stage product being developed by Jasper Therapeutics for Lower-risk Myelodysplastic Syndrome. The current trial status is terminated. This product is registered under clinical trial identifier NCT05903274. Target conditions include Lower-risk Myelodysplastic Syndrome.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05903274Phase 1Terminated

Competing Products

1 competing product in Lower-risk Myelodysplastic Syndrome

See all competitors
ProductCompanyStageHype Score
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
22

Other Products from Jasper Therapeutics

BriquilimabPhase 2
44
BriquilimabPhase 1/2
33
BriquilimabPhase 1/2
33
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1/2
33
Humanized anti-CD117 Monoclonal Antibody (JSP191)Phase 1
25